详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors

64| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Huazhong Univ Sci & Technol,Affiliated Tongji Hosp,Tongji Med Coll,Canc Res Ctr,Dept Biliary & Pancreat Surg,Wuhan 430030,Hubei,Peoples R China [2]Univ Heidelberg Hosp, Dept Gen & Transplant Surg, D-69120 Heidelberg, Germany

出处：

DOI：

关键词： histone deacetylase (HDAC) HDAC inhibitors (HDACIs) microarray transforming acidic coiled-coil-containing protein 3 (TACC3) cholangiocarcinoma (CCA)

摘要：

Histone deacetylases (HDACs) have been implicated in multiple malignant tumors, and HDAC inhibitors (HDACIs) exert anti-cancer effects. However, the expression of HDACs and the anti-tumor mechanism of HDACIs in cholangiocarcinoma (CCA) have not yet been elucidated. In this study, we found that expression of HDACs 2, 3, and 8 were up-regulated in CCA tissues and those patients with high expression of HDAC2 and/or HDAC3 had a worse prognosis. In CCA cells, two HDACIs, trichostatin (TSA) and vorinostat (SAHA), suppressed proliferation and induced apoptosis and G2/M cycle arrest. Microarray analysis revealed that TACC3 mRNA was down-regulated in CCA cells treated with TSA. TACC3 was highly expressed in CCA tissues and predicted a poor prognosis in CCA patients. TACC3 knockdown induced G2/M cycle arrest and suppressed the invasion, metastasis, and proliferation of CCA cells, both in vitro and in vivo. TACC3 overexpression reversed the effects of its knockdown. These findings suggest TACC3 may be a useful prognostic biomarker for CCA and is a potential therapeutic target for HDACIs.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2015]版：

大类 | 1 区

医学

小类 | 2 区肿瘤学 3 区细胞生物学

最新[2025]版：

无

JCR分区：

出版当年[2014]版：

Q1 ONCOLOGY Q1 CELL BIOLOGY

最新[2023]版：

无

影响因子： 0 最新[2023版] 0 最新五年平均 6.359 出版当年[2014版] 6.368 出版当年五年平均 6.627 出版前一年[2013版] 5.008 出版后一年[2015版]

第一作者：

第一作者单位： [1]Huazhong Univ Sci & Technol,Affiliated Tongji Hosp,Tongji Med Coll,Canc Res Ctr,Dept Biliary & Pancreat Surg,Wuhan 430030,Hubei,Peoples R China

通讯作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Conversion therapy for advanced cholangiocarcinoma in the era of molecular targeted therapy and immune therapy [2]RNF4 promotes tumorigenesis, therapy resistance of cholangiocarcinoma and affects cell cycle by regulating the ubiquitination degradation of p27kip1 in the nucleus [3]Knockdown of UBE2I inhibits tumorigenesis and enhances chemosensitivity of cholangiocarcinoma via modulating p27kip1 nuclear export [4]Contrast enhanced ultrasound in mixed hepatocellular cholangiocarcinoma: Case series and review of the literature [5]A Potential circRNA-miRNA-mRNA Regulatory Network in Asthmatic Airway Epithelial Cells Identified by Integrated Analysis of Microarray Datasets [6]Aberrantly expressed lncRNAs identified by microarray analysis in CD4+T cells in asthmatic patients [7]Multiple rather than specific autoantibodies were identified in irritable bowel syndrome with HuProt™ proteome microarray [8]MicroRNAs Associated with Keloids Identified by Microarray Analysis and In Vitro Experiments [9]Integrated analysis of multiple microarray studies to identify novel gene signatures in preeclampsia [10]Screening genes associated with melanoma using a combined analysis of mRNA and methylation microarray